| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Life Sciences Division, Arthur D. Little, Inc., Cambridge, Massachusetts
Some of the toxicologic problems associated with the use of newer agents such as the phthalanilides have been presented. In lieu of the discovery of anti-leukemic agents with much improved therapeutic indices, it is perhaps encouraging in terms of potential combination therapy that limiting toxicologic problems differ. Methods have been developed or adapted which indicate that these toxicologic problems may not be associated with all structurally related compounds with anti-leukemic activity. It is suggested that the area of selective reduction in toxicity by the administration of toxicity-alleviating agents merits increased attention.
1 The experimental studies included in this report have been supported by contract SA-43-ph-3789, Cancer Chemotherapy National Service Center, National Cancer Institute.
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |